More effective therapies could potentially be introduced
thanks to a new magnetic resonance spectroscopy technique that can accurately
measure how well the mitochondria are functioning in patients with Amyotrophic
Lateral Sclerosis (ALS.) This non-invasive procedure may help measure the
efficacy of treatments for ALS (also known as Motor Neuron Disease [MND])
patients.
Scientists from Sheffield Institute for Translational
Neuroscience (SITraN) from the University of Sheffield in the United Kingdom
tested how the 31-phosphorus magnetic resonance spectroscopy performed,
publishing their findings in the January 13 issue of Brain.
Lead study author Dr. Matilde Sassani, a neurodegeneration
researcher at Sheffield, said, “In this study, we found that phosphocreatine
levels were depleted in the brain compared to healthy controls and, in this
muscle, we found that inorganic phosphates were elevated in patients with MND.
Both of these findings are consistent with mitochondrial dysfunction occurring
in these people living with MND.”
People with ALS suffer from impaired mitochondrial function,
so having a technique that can effectively and accurately measure mitochondrial
activity could be critical to treatment.
In the study, the imaging technique was used to measure a
chemical involved in the cell’s energy metabolism. ALS patients were compared
to healthy age and gender-matched controls. The procedure resembles an MRI; the
process allows investigators to capture a direct measurement of chemicals. This
snapshot gives them the appropriate data needed to calculate a comprehensive
view of a patient with MND.
Senior author Dr. Thomas Jenkins, a clinical senior lecturer
at SITraN, said the newfound technique could pave the way for more effective
MND treatments and potentially measure how effective medications are.
Jenkins said, “Treatments that aim to rescue mitochondrial
function in MND are being investigated in labs around the world. This
non-invasive tool can demonstrate whether medications in development are
successfully targeting mitochondria, which is an important step in selecting
treatments to take through clinical trials.”
Patients with other forms of neurodegenerative diseases
might also benefit from this technique, though further research is needed.
To read additional
information, refer to the article
in the latest issue of Brain, a Journal of Neurology.
Acceletronics is
an industry leader in delivering the best equipment performance and service
reliability from CT Scanners and Linear Accelerators across all major brands
and models. Call 610-524-3300 or
visit our website: https://www.acceletronics.com.
Written by the digital marketing staff at Creative
Programs & Systems: www.cpsmi.com.